OBI announces termination of BCVax, OBI-866, and OBI-999

1.Date of occurrence of the event:2023/12/20 2.Company name:OBI Pharma, Inc. 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):head office 4.Reciprocal shareholding ratios: NA 5.Cause of occurrence: After prudent evaluation, the Company’s Board of Directors has determined to terminate the development of BCVax, OBI-866, and OBI-999, and to focus existing resources on other projects. […]

This article is password protected.

To view the content, please enter your password in the field below